758 related articles for article (PubMed ID: 34396154)
21. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
22. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
Mahil SK; Bechman K; Raharja A; Domingo-Vila C; Baudry D; Brown MA; Cope AP; Dasandi T; Graham C; Lechmere T; Malim MH; Meynell F; Pollock E; Seow J; Sychowska K; Barker JN; Norton S; Galloway JB; Doores KJ; Tree TIM; Smith CH
Lancet Rheumatol; 2021 Sep; 3(9):e627-e637. PubMed ID: 34258590
[TBL] [Abstract][Full Text] [Related]
23. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
24. Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
Hamad Saied M; van Straalen JW; de Roock S; Verduyn Lunel FM; de Wit J; de Rond LGH; Van Nieuwenhove E; Vastert BJ; van Montfrans JM; van Royen-Kerkhof A; de Joode-Smink GCJ; Swart JF; Wulffraat NM; Jansen MHA
Vaccine; 2024 Feb; 42(5):1145-1153. PubMed ID: 38262809
[TBL] [Abstract][Full Text] [Related]
25. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
[TBL] [Abstract][Full Text] [Related]
26. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
27. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.
Mair MJ; Berger JM; Berghoff AS; Starzer AM; Ortmayr G; Puhr HC; Steindl A; Perkmann T; Haslacher H; Strassl R; Tobudic S; Lamm WW; Raderer M; Mitterer M; Fuereder T; Fong D; Preusser M
JAMA Oncol; 2022 Jan; 8(1):106-113. PubMed ID: 34591965
[TBL] [Abstract][Full Text] [Related]
28. Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study.
Simon D; Tascilar K; Fagni F; Kleyer A; Krönke G; Meder C; Dietrich P; Orlemann T; Mößner J; Taubmann J; Mutlu MY; Knitza J; Kemenes S; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Minopoulou I; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
Lancet Rheumatol; 2022 Sep; 4(9):e614-e625. PubMed ID: 35966645
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
30. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.
Prasad N; Bansal SB; Yadav B; Manhas N; Yadav D; Gautam S; Kushwaha R; Singh A; Bhadauria D; Yachha M; Behera MR; Kaul A
Front Immunol; 2022; 13():911738. PubMed ID: 35844596
[TBL] [Abstract][Full Text] [Related]
31. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Deepak P; Kim W; Paley MA; Yang M; Carvidi AB; Demissie EG; El-Qunni AA; Haile A; Huang K; Kinnett B; Liebeskind MJ; Liu Z; McMorrow LE; Paez D; Pawar N; Perantie DC; Schriefer RE; Sides SE; Thapa M; Gergely M; Abushamma S; Akuse S; Klebert M; Mitchell L; Nix D; Graf J; Taylor KE; Chahin S; Ciorba MA; Katz P; Matloubian M; O'Halloran JA; Presti RM; Wu GF; Whelan SPJ; Buchser WJ; Gensler LS; Nakamura MC; Ellebedy AH; Kim AHJ
Ann Intern Med; 2021 Nov; 174(11):1572-1585. PubMed ID: 34461029
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates.
Lodde GC; Fiedler M; Dittmer U; Placke JM; Jansen P; Becker JC; Zimmer L; Livingstone E; Schadendorf D; Sondermann W; Ugurel S
Front Oncol; 2022; 12():879876. PubMed ID: 36091146
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
[TBL] [Abstract][Full Text] [Related]
35. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
36. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
37. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
[TBL] [Abstract][Full Text] [Related]
38. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
Diamantopoulos PT; Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Giannakopoulou N; Vardaka M; Mpouhla A; Mastrogianni E; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ther Adv Hematol; 2022; 13():20406207221090150. PubMed ID: 35646300
[TBL] [Abstract][Full Text] [Related]
40. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q; Haggenburg S; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; van Meerloo J; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Vogels-Nooijen S; Rots N; van Beek J; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
EClinicalMedicine; 2023 Jul; 61():102040. PubMed ID: 37337616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
